This facility has fabulous quality systems, processes and documentation procedures. In-house developed software records and ensures strict compliances of laid down procedures at every stage of manufacturing.
This facility is among the few pharmaceutical formulation facilities in the country that has approvals from the most stringent authorities in the world like USFDA and WHO Prequalification.
This facility is dedicated to meet the requirements of Emerging Markets, equipped with suitable machines for each section, this facility also keeps sharp eye on environment protection.
This facility is Ajanta's only Active Pharmaceutical Ingredient (API) (also known as bulk drug, used as raw material for our formulation plants) facility committed mainly for captive consumption.
The facility has been specially constructed for catering to the requirements of markets like USA, WHO and Emerging Markets. The facility has received successful inspection clearance from US FDA without any observation in April 2017. It has capacity to manufacture annually about 1,740 Million Tablets, 216 Million Capsules and 150 Million Powder sachets. Facility has been built complying international standards.
In early 2016 APL had acquired a plot of land in Kokjhar, District Kamrup (R), Guwahati, Assam. Company has successfully operationalized Phase 1 of the facility on 22nd January 2017 for Tablets & Jelly, which was built in record time of 12 months. This facility has been planned keeping in view the growth for another 5 years in Domestic Market.
Complying with WHO cGMP guidelines, this facility follows all the quality parameters followed by Ajanta Pharma in India and has excellent quality control section to ensure best international quality for its products. Ministry of Health delegations from several countries have inspected, audited and approved this manufacturing facility.